USA – Drug industry groups oppose FDA’s drug importation plan

Pharmaceutical industry groups and Canadian pharmacists staunchly opposed the US plan to allow states and drug companies to import certain prescription drugs from Canada and other countries in an effort to lower costs.
 
In comments submitted to the public docket for the US Food and Drug Administration’s (FDA) proposed rule on importation, the two groups pushed back on the plan, citing insignificant cost savings, safety concerns and the capacity of Canada’s drug supply chain to meet US demand.
 
The comments come as states around the country, including ConnecticutNew MexicoMaineOklahomaVermont and Wyoming weigh measures to move forward with importing drugs.
 
In its 81-page comment, the Pharmaceutical Research and Manufacturers of America (PhRMA) calls on the Department of Health and Human Services to abandon the proposal and withdraw the notice of proposed rulemaking.
 
The pharmaceutical industry group also questions the safety of drugs that would be imported under the proposal and argued that the cost savings it would achieve would not make a significant dent in US health care spending…